Most of the Sorafenib-like small molecules (Table S1) could significantly induce the expression of PHGDH, PSAT1, and PSPH across various types of cancer cells (Fig. 6d), suggesting that induction of SSP is a common event in response to Sorafenib-like small molecules treatment and targeting PHGDH may be applied in a wider range of combinational treatment for a more variety of cancer types. Here, PHGDH is linked to cancer.